drugset / Trial / NCT00428545
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ (bevacizumab) and Velcade™ (bortezomib) that can be given in combination to patients with a metastatic or unresectable advanced malignancy. The safety and effectiveness of this drug combination will also be studied.
Timeline
- Start
- 2007-01
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Bortezomib | Small molecule | 0.7 mg/m2 | Intravenous |